We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/3/2018 11:35 | Happy holding, just arrived in South of France, welcome gift, the action has only just started! | ny boy | |
28/3/2018 11:30 | Bid would have to beat the Abvie offer surely | mbmiah | |
28/3/2018 11:20 | Just remembering how stressful (and exciting) the AbbVie bid situation was. Will be interesting to experience that all over again if a bid is made. Glad Susan Kilby is still chair - she was instrumental in exacting a good price and terms from AbbVie including the break clause. | romeike | |
28/3/2018 11:16 | We all know this worth 50+. If the bid comes, that's where we're headed. | ruethewhirl | |
28/3/2018 11:14 | You think shire was volatile before? Next wee while will be a rollercoaster. Bids, retractions, rumour mill in high gear, speculators piling in. | ruethewhirl | |
28/3/2018 11:12 | At the very least it will bring some welcome focus on to the fundamentals at Shire and the strong performance rather than the obsessive negative narrative around a potential neuroscience spin off. It is encouraging that in Takeda statements it shows interest in both aspects of the Shore business, neuro, to complement their existing operation and also the rare diseases. | romeike | |
28/3/2018 11:04 | might encourage some others to consider a bid ... | mister md | |
28/3/2018 11:01 | Any offer would have to be at a very serious premium to the current share price. I would say £52 - £58. Certainly would be annoyed to see them agree to anything less than £52 as I think Shire could get back to that level on their own with no need for a deal. | romeike | |
28/3/2018 10:58 | Dooes Takeda have the chedder for this scale of takeover? stories last year saying their planned purchases would be in the $15-$20bn mark this is far larger especially after their spends this year already. on the otherhand thrilled to be back in profit of this fella | hortensius | |
28/3/2018 10:42 | Small in/out for me. Congrats guys, realise some of you are holding in quantity, well done for keeping the faith, that was not easy to do. | essentialinvestor | |
28/3/2018 10:41 | My Shire holding just exploded back into profit, been a shareholder for over a decade. If there is an offer I hope it is a sensible £50+. | romeike | |
28/3/2018 10:41 | Yep considering an approach. Preliminary and exploratory sage. No approach has been made to the board and no certainty they will so I think that is keeping a lid on the rise. Hopefully smokes out other bidders. | billytkid2 | |
28/3/2018 10:41 | Japan’s Takeda Pharmaceutical said on Wednesday that it is “considering making an approach” to buy Shire, the Irish drugmaker. Takeda said its consideration is still “at a preliminary and exploratory stage and no approach has been made to the board of Shire.” | kamitora | |
28/3/2018 10:40 | Well done to all that stayed with Shire, you all deserve that good luck :o) | jpjohn1 | |
28/3/2018 10:39 | Where is nyboy? Got in around 3000. Great call...!!! | ruethewhirl | |
28/3/2018 10:38 | Takada. No further info at present. Congratulations to us, the true believers. Knew that there was value here. | ruethewhirl | |
28/3/2018 10:37 | from CNBC Takeda confirming approach | dechy | |
28/3/2018 10:25 | shire in play !!! | alchemy30 | |
28/3/2018 10:20 | Billy, thanks for that. I'm tempted to buy back a few. | essentialinvestor | |
28/3/2018 10:17 | Apparently the stock is up as Shire could be a beneficiary from worries about the safety of Roches Hemlibra. The Hemopjilia Federation have highlighted the deaths of 5 patients on that drug. Some other companies dealing in that space are also up. | billytkid2 | |
28/3/2018 10:11 | Could be folks are quitting tech for something more defensive. Seems inevitable there will be a steep correction over in the US for certain stocks that have climbed to ridiculous levels. | romeike |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions